Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
Nelli Bejanyan(Moffitt Cancer Center), Marco L. Davila(University of South Florida), José A. Guevara-Patiño(Moffitt Cancer Center), Jongphil Kim(Moffitt Cancer Center), Abu‐Sayeef Mirza(University of South Florida), Farhad Khimani(Moffitt Cancer Center), Hany Elmariah(Moffitt Cancer Center), Frederick L. Locke(Moffitt Cancer Center), David A. Sallman(Moffitt Cancer Center), Bin Yu(Moffitt Cancer Center), Christopher Cubitt(Moffitt Cancer Center), Jeffrey E. Lancet(Cornell University), Kumar Karyampudi(Moffitt Cancer Center), Hien Liu(Moffitt Cancer Center), Claudio Anasetti(Moffitt Cancer Center), Sean Yoder(Moffitt Cancer Center), Cheryl A. Cox(Moffitt Cancer Center), Justin C. Boucher, José L. Ochoa-Bayona(Moffitt Cancer Center), Melissa Lowden(Moffitt Cancer Center), Xiaofei Song(Jiangsu University), Joseph A. Pidala(Moffitt Cancer Center), Kayla Reid(Moffitt Cancer Center), Lia Perez(Moffitt Cancer Center), Rawan Faramand(Moffitt Cancer Center)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k